Enliven Therapeutics

Forecast & Rating12 analysts currently cover Enliven Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $73.90, about 47.1% upside from the current price of $50.24. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 14.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Enliven Therapeutics closely still see room for the stock to rise. Data as of Sep 15, 2026; for reference only and not investment advice.